dIRF4

dIRF4 is a first-in-class small molecule proteolysis targeting chimera (PROTAC) designed to induce the selective degradation of Interferon Regulatory Factor 4 (IRF4). IRF4 is an oncogenic transcription factor and a critical dependency in multiple myeloma and other hematological malignancies. Developed by researchers at the Dana-Farber Cancer Institute, dIRF4 consists of a ligand targeting the SPI1 (PU.1) binding pocket within the IRF4 interferon accessory domain (IAD) linked to a cereblon (CRBN) E3 ligase recruiter. By facilitating the recruitment of IRF4 to the CRBN E3 ligase complex, dIRF4 triggers the ubiquitination and subsequent proteasomal degradation of IRF4. In preclinical studies, dIRF4 has demonstrated potent cytotoxic effects in multiple myeloma cell lines and favorable pharmacokinetic profiles in vivo.